SITEPRIDE DM 500

About

SITEPRIDE DM 500 combines Sitagliptin, a dipeptidyl peptidase-4 (DPP-4) inhibitor, and Metformin 500mg, a biguanide, for the comprehensive management of type 2 diabetes mellitus. Sitagliptin enhances the body's natural incretin system, increasing insulin release and decreasing glucagon secretion in a glucose-dependent manner. Metformin primarily reduces hepatic glucose production, decreases intestinal glucose absorption, and improves insulin sensitivity in peripheral tissues. This dual-action therapy targets multiple pathophysiological defects of type 2 diabetes, including impaired insulin secretion, increased hepatic glucose output, and insulin resistance. The combination is particularly effective for patients who have not achieved adequate glycemic control with monotherapy or who require a more robust approach to lower HbA1c levels. It offers the benefits of both agents, including a low risk of weight gain and a favorable cardiovascular profile associated with metformin.

Uses

• Management of type 2 diabetes mellitus.
• To improve glycemic control in adults.
• When diet and exercise are insufficient.
• As an add-on to other antidiabetic agents.

Directions For Use

Take orally with meals, usually once or twice daily, as directed by your physician. Swallow the tablet whole with water.

Benefits

• Effective blood sugar control.
• Addresses multiple diabetes pathways.
• Reduces HbA1c levels significantly.
• Low risk of weight gain.
• Improved insulin sensitivity.
• Convenient combination therapy.

Side Effects

• Nausea
• Diarrhea
• Abdominal pain
• Metallic taste
• Headache
• Nasopharyngitis
• Hypoglycemia (especially with other agents)
• Lactic acidosis (rare, with Metformin)
• Vitamin B12 deficiency (long-term Metformin)
• Joint pain
• Back pain
• Upper respiratory infection

Safety Measures

• Alcohol - Avoid excessive alcohol intake due to increased risk of hypoglycemia and lactic acidosis (Metformin).
• Pregnancy - Not recommended during pregnancy. Insulin is generally preferred for glycemic control in pregnant women.
• Breastfeeding - Avoid during breastfeeding as components may pass into breast milk. Consult a doctor.
• Liver - Contraindicated in severe hepatic impairment due to increased risk of lactic acidosis. Use with caution in other liver conditions.
• Kidney - Contraindicated in severe renal impairment (eGFR <30 mL/min/1.73m²) due to risk of lactic acidosis. Dose adjustment needed for moderate impairment.
• Lung - Use with caution in severe acute or chronic lung disease due to potential for hypoxia, increasing lactic acidosis risk.

Disclaimer

MedEHub is committed to delivering reliable, expert-reviewd information to help consumers make informed health decisions. However, the content provided on this website is for informational purposes only and is not intended to replace professional medical advice, diagnosis or treatment.

Always consult your doctor for any medical concerns, and discuss your questions about health conditions or medications with a qualified healthcare professional. Do not ignore or delay seeking professional medical advice based on information found on Med E Hub.

Our goal is to complement, not replace, the essential doctor-patient relationship.